REG - Immupharma PLC - Share Price Volatility

ImmuPharmaAnnouncement

11/12/2019 12:50

RNS Number : 5515W
Immupharma PLC
11 December 2019
 


11 December 2019
 
ImmuPharma PLC
("ImmuPharma" or the "Company")
 
SHARE PRICE VOLATILITY
 
ImmuPharma PLC (LSE:IMM), a specialist drug discovery and development company, announces that  following the recently announced licensing and development agreement with Avion, the US speciality pharmaceutical company, in which Avion will fund an international Phase III trial for our lead programme, Lupuzor™, we note the volatility in the Company's share price and speculation concerning a possible fundraising.  The Board can confirm that the Company is adequately funded and has no intention of raising funds.
 
 
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
 
 




 
For further information please contact:
 




ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chairman


+ 44 (0) 207 152 4080




Dimitri Dimitriou, Chief Executive Officer


 




Lisa Baderoon, Head of Investor Relations


+ 44 (0) 7721 413496
 




SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Vassil Kirtchev
 
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes
 
SI Capital (Joint Broker)
Nick Emerson
 


+44 (0) 203 368 8974
 
 
 
+44 (0) 203 815 8880
 
 
+44 (0) 1483 413500
 
 




 


 




 


 




 




Notes to Editors
 
About ImmuPharma PLC
ImmuPharma PLC (AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. For additional information about ImmuPharma please visit www.immupharma.com. 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCBDBDDLSBBGCB